NU 578 Unit 4 Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NU 578 Unit 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide covers gastrointestinal pharmacology for the NU 578 Unit
4 Exam. It includes 250 verified questions and answers, reflecting the latest 2026/2027 curriculum
updates. Designed to help students achieve a top score, this resource provides detailed rationales and
evidence-based explanations. Ideal for nursing and advanced practice students seeking a complete A+
guide.
Key Features:
Gastrointestinal drug classifications and mechanisms
Pharmacokinetics and pharmacodynamics of GI agents
Clinical application and patient education
Adverse effects, contraindications, and drug interactions
Dosage calculations and administration guidelines
Evidence-based practice and current guidelines
Updates for 2026:
- Incorporated 2026/2027 FDA approvals and label changes
- Revised rationales to align with latest clinical practice guidelines
- Added new questions on biologic therapies for IBD
- Updated drug interaction tables and contraindication lists
- Enhanced coverage of proton pump inhibitors and H2 antagonists
Abstract:
This examination preparation document for NU 578 Unit 4 focuses on gastrointestinal pharmacology,
encompassing 250 verified questions and answers. The content is meticulously aligned with the 2026/2027
academic curriculum and current clinical guidelines. Each question is accompanied by a detailed rationale
explaining the correct answer and common misconceptions, facilitating deep understanding. The guide covers all
major drug classes affecting the gastrointestinal system, including antacids, antiemetics, laxatives, antidiarrheals,
and agents for inflammatory bowel disease. Special emphasis is placed on pharmacokinetic principles, adverse
effect profiles, and nursing considerations. Updated to reflect the latest evidence-based practice, this resource
ensures students are well-prepared for exam success and clinical application.
Keywords:
Gastrointestinal pharmacology, NU 578 exam prep, 250 verified questions, 2026/2027 update, Nursing
pharmacology, GI drug mechanisms, Advanced practice nursing
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is identified, followed
by a concise rationale explaining why it is correct and why the other options are incorrect. Distractor explanations
highlight common errors and misconceptions to reinforce learning.
Compliance Checklist:
All questions verified against 2026/2027 curriculum standards
Rationales cite current clinical guidelines and drug references
Content reviewed by subject matter experts
Page 1
, Answers graded A+ for accuracy and completeness
Updated to include recent FDA approvals and safety alerts
Suitable for self-assessment and exam simulation
Content Area Overview:
Content Area Questions Key Topics Weight
Antacids and Acid-Reducing 1-40 Proton pump inhibitors, H2 antagonists, 16%
Agents antacids, mechanism of action, adverse
effects, drug interactions
Antiemetics and Prokinetics 41-80 Serotonin antagonists, dopamine 16%
antagonists, NK1 receptor antagonists,
prokinetic agents, clinical indications
Laxatives and Antidiarrheals 81-120 Bulk-forming, stimulant, osmotic, stool 16%
softeners; opioid antidiarrheals, bismuth
subsalicylate, probiotics
Inflammatory Bowel Disease 121-160 5-aminosalicylates, corticosteroids, 16%
Agents immunomodulators, biologic therapies
(anti-TNF, integrin antagonists)
Pancreatic Enzymes and Bile 161-200 Pancrelipase, cholestyramine, bile acid 16%
Acid Sequestrants malabsorption, dosing considerations
Miscellaneous GI Agents 201-250 Antispasmodics, antibiotics for H. pylori, 20%
sucralfate, misoprostol, octreotide
Page 2
,Q1. A patient with chronic gastroesophageal reflux disease (GERD) has been taking omeprazole 20 mg daily
for 6 months. Despite adherence, symptoms persist. The prescriber considers switching to a different PPI.
Which of the following pharmacodynamic principles best explains why a different PPI may be more effective
in this patient?
A. PPIs differ in their pKa values, affecting the rate of accumulation in the acidic canaliculi of parietal cells.
B. All PPIs have identical bioavailability and half-life, so switching would not alter efficacy.
C. Omeprazole is a prodrug, whereas other PPIs are active compounds that do not require acid activation.
D. The patient likely has a CYP2C19 polymorphism that reduces omeprazole metabolism, increasing its
efficacy.
Correct Answer: A. PPIs differ in their pKa values, affecting the rate of accumulation in the acidic canaliculi
of parietal cells.
Rationale: PPIs differ in pKa values, which influences how rapidly they accumulate in the acidic environment of
parietal cell canaliculi. A PPI with a higher pKa (e.g., lansoprazole) may achieve higher concentrations more
quickly, potentially improving symptom control in some patients. Option B is false because PPIs vary in
bioavailability and half-life. Option C is incorrect as all PPIs are prodrugs requiring acid activation. Option D
describes a scenario that would increase efficacy, not reduce it.
Why Wrong:
B - PPIs have different pharmacokinetic profiles, including bioavailability and half-life, so switching may
alter efficacy.
C - All PPIs are prodrugs that require activation in the acidic environment of parietal cells.
D - Reduced CYP2C19 metabolism would increase omeprazole exposure and efficacy, not decrease it.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 62
Q2. A patient with diabetic gastroparesis is prescribed metoclopramide. Which of the following statements
accurately describes the mechanism by which metoclopramide enhances gastric emptying?
A. Selective 5-HT3 receptor antagonism in the chemoreceptor trigger zone.
B. Dopamine D2 receptor antagonism in the gut and central nervous system.
C. Muscarinic M1 receptor agonism increasing lower esophageal sphincter tone.
D. Inhibition of acetylcholinesterase, prolonging acetylcholine action at neuromuscular junctions.
Correct Answer: B. Dopamine D2 receptor antagonism in the gut and central nervous system.
Rationale: Metoclopramide acts primarily as a dopamine D2 receptor antagonist in the gut, which enhances
gastric motility and accelerates gastric emptying. It also has central antiemetic effects via D2 antagonism in the
CTZ. Option A describes ondansetron, not metoclopramide. Option C is partially true but not the primary
mechanism; metoclopramide also has weak 5-HT4 agonist activity. Option D describes neostigmine, a different
drug.
Why Wrong:
A - Selective 5-HT3 antagonism is the mechanism of ondansetron, not metoclopramide.
C - Metoclopramide does not directly agonize muscarinic receptors; it enhances cholinergic activity
indirectly.
D - Acetylcholinesterase inhibition is the mechanism of neostigmine, not metoclopramide.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 63
Q3. A patient undergoing chemotherapy is prescribed a 5-HT3 receptor antagonist for prevention of acute
emesis. Which of the following properties of this drug class contributes most to its selectivity and reduced
extrapyramidal side effects compared to older antiemetics?
A. High affinity for dopamine D2 receptors in the gut.
B. Selective blockade of serotonin receptors in the area postrema and vagal afferents.
C. Ability to cross the blood-brain barrier and act on the vestibular system.
D. Antagonism of histamine H1 receptors in the vomiting center.
Page 3
, Correct Answer: B. Selective blockade of serotonin receptors in the area postrema and vagal afferents.
Rationale: 5-HT3 receptor antagonists (e.g., ondansetron) selectively block serotonin receptors located in the area postrema
(chemoreceptor trigger zone) and on vagal nerve terminals in the gut, which are key in initiating the emetic reflex. This
selectivity avoids dopamine receptor blockade, thus minimizing extrapyramidal side effects. Option A describes
metoclopramide. Option C is not a desired property; these drugs have limited CNS penetration. Option D describes
antihistamines.
Why Wrong:
A - Dopamine D2 antagonism is associated with extrapyramidal symptoms, not selectivity.
C - Vestibular system action is not a major mechanism for 5-HT3 antagonists; they act primarily on CTZ and vagus.
D - H1 antagonism is characteristic of antihistamines used for motion sickness.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 63
Q4. A patient with chronic constipation is prescribed lubiprostone. Which of the following best describes the
mechanism of action of this drug?
A. Osmotic retention of water in the intestinal lumen via non-absorbable sugars.
B. Activation of chloride channels (ClC-2) on intestinal epithelial cells, increasing fluid secretion.
C. Stimulation of peristalsis via 5-HT4 receptor agonism.
D. Inhibition of sodium-glucose cotransporters, reducing water absorption.
Correct Answer: B. Activation of chloride channels (ClC-2) on intestinal epithelial cells, increasing fluid
secretion.
Rationale: Lubiprostone is a chloride channel activator that specifically targets ClC-2 channels on the apical
membrane of intestinal epithelial cells. Activation of these channels increases chloride secretion into the lumen,
followed by sodium and water, resulting in softer stools and increased motility. Option A describes lactulose.
Option C describes prucalopride. Option D describes SGLT2 inhibitors, which are used for diabetes.
Why Wrong:
A - Osmotic laxatives like lactulose work by non-absorbable sugars, not chloride channel activation.
C - 5-HT4 agonism is the mechanism of prucalopride, not lubiprostone.
D - Inhibition of sodium-glucose cotransporters is unrelated to lubiprostone's mechanism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 65
Q5. A patient with ulcerative colitis is being treated with mesalamine. Which of the following statements
regarding the pharmacokinetics of mesalamine is most accurate?
A. Mesalamine is extensively absorbed in the small intestine and undergoes hepatic metabolism to an inactive
metabolite.
B. Mesalamine is released in the colon via pH-dependent or bacterial-dependent mechanisms, minimizing
systemic absorption.
C. Mesalamine requires activation by intestinal bacteria to form its active metabolite, 5-aminosalicylic acid.
D. Mesalamine is administered intravenously to achieve high colonic concentrations.
Correct Answer: B. Mesalamine is released in the colon via pH-dependent or bacterial-dependent
mechanisms, minimizing systemic absorption.
Rationale: Mesalamine (5-ASA) is formulated with various delivery systems (e.g., pH-dependent coatings,
bacterial-dependent release) to ensure it reaches the colon, where it acts topically. This design minimizes systemic
absorption and reduces side effects. Option A is incorrect because mesalamine is not extensively absorbed; it acts
locally. Option C is incorrect because mesalamine is already the active moiety; sulfasalazine requires bacterial
cleavage. Option D is incorrect because mesalamine is given orally or rectally, not IV.
Why Wrong:
A - Mesalamine is minimally absorbed and acts locally in the colon, not extensively absorbed.
C - Mesalamine is the active form; sulfasalazine requires bacterial reduction to release mesalamine.
D - Mesalamine is not administered intravenously; it is given orally or rectally for topical effect.
Page 4
Verified Questions
NU 578 Unit 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide covers gastrointestinal pharmacology for the NU 578 Unit
4 Exam. It includes 250 verified questions and answers, reflecting the latest 2026/2027 curriculum
updates. Designed to help students achieve a top score, this resource provides detailed rationales and
evidence-based explanations. Ideal for nursing and advanced practice students seeking a complete A+
guide.
Key Features:
Gastrointestinal drug classifications and mechanisms
Pharmacokinetics and pharmacodynamics of GI agents
Clinical application and patient education
Adverse effects, contraindications, and drug interactions
Dosage calculations and administration guidelines
Evidence-based practice and current guidelines
Updates for 2026:
- Incorporated 2026/2027 FDA approvals and label changes
- Revised rationales to align with latest clinical practice guidelines
- Added new questions on biologic therapies for IBD
- Updated drug interaction tables and contraindication lists
- Enhanced coverage of proton pump inhibitors and H2 antagonists
Abstract:
This examination preparation document for NU 578 Unit 4 focuses on gastrointestinal pharmacology,
encompassing 250 verified questions and answers. The content is meticulously aligned with the 2026/2027
academic curriculum and current clinical guidelines. Each question is accompanied by a detailed rationale
explaining the correct answer and common misconceptions, facilitating deep understanding. The guide covers all
major drug classes affecting the gastrointestinal system, including antacids, antiemetics, laxatives, antidiarrheals,
and agents for inflammatory bowel disease. Special emphasis is placed on pharmacokinetic principles, adverse
effect profiles, and nursing considerations. Updated to reflect the latest evidence-based practice, this resource
ensures students are well-prepared for exam success and clinical application.
Keywords:
Gastrointestinal pharmacology, NU 578 exam prep, 250 verified questions, 2026/2027 update, Nursing
pharmacology, GI drug mechanisms, Advanced practice nursing
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is identified, followed
by a concise rationale explaining why it is correct and why the other options are incorrect. Distractor explanations
highlight common errors and misconceptions to reinforce learning.
Compliance Checklist:
All questions verified against 2026/2027 curriculum standards
Rationales cite current clinical guidelines and drug references
Content reviewed by subject matter experts
Page 1
, Answers graded A+ for accuracy and completeness
Updated to include recent FDA approvals and safety alerts
Suitable for self-assessment and exam simulation
Content Area Overview:
Content Area Questions Key Topics Weight
Antacids and Acid-Reducing 1-40 Proton pump inhibitors, H2 antagonists, 16%
Agents antacids, mechanism of action, adverse
effects, drug interactions
Antiemetics and Prokinetics 41-80 Serotonin antagonists, dopamine 16%
antagonists, NK1 receptor antagonists,
prokinetic agents, clinical indications
Laxatives and Antidiarrheals 81-120 Bulk-forming, stimulant, osmotic, stool 16%
softeners; opioid antidiarrheals, bismuth
subsalicylate, probiotics
Inflammatory Bowel Disease 121-160 5-aminosalicylates, corticosteroids, 16%
Agents immunomodulators, biologic therapies
(anti-TNF, integrin antagonists)
Pancreatic Enzymes and Bile 161-200 Pancrelipase, cholestyramine, bile acid 16%
Acid Sequestrants malabsorption, dosing considerations
Miscellaneous GI Agents 201-250 Antispasmodics, antibiotics for H. pylori, 20%
sucralfate, misoprostol, octreotide
Page 2
,Q1. A patient with chronic gastroesophageal reflux disease (GERD) has been taking omeprazole 20 mg daily
for 6 months. Despite adherence, symptoms persist. The prescriber considers switching to a different PPI.
Which of the following pharmacodynamic principles best explains why a different PPI may be more effective
in this patient?
A. PPIs differ in their pKa values, affecting the rate of accumulation in the acidic canaliculi of parietal cells.
B. All PPIs have identical bioavailability and half-life, so switching would not alter efficacy.
C. Omeprazole is a prodrug, whereas other PPIs are active compounds that do not require acid activation.
D. The patient likely has a CYP2C19 polymorphism that reduces omeprazole metabolism, increasing its
efficacy.
Correct Answer: A. PPIs differ in their pKa values, affecting the rate of accumulation in the acidic canaliculi
of parietal cells.
Rationale: PPIs differ in pKa values, which influences how rapidly they accumulate in the acidic environment of
parietal cell canaliculi. A PPI with a higher pKa (e.g., lansoprazole) may achieve higher concentrations more
quickly, potentially improving symptom control in some patients. Option B is false because PPIs vary in
bioavailability and half-life. Option C is incorrect as all PPIs are prodrugs requiring acid activation. Option D
describes a scenario that would increase efficacy, not reduce it.
Why Wrong:
B - PPIs have different pharmacokinetic profiles, including bioavailability and half-life, so switching may
alter efficacy.
C - All PPIs are prodrugs that require activation in the acidic environment of parietal cells.
D - Reduced CYP2C19 metabolism would increase omeprazole exposure and efficacy, not decrease it.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 62
Q2. A patient with diabetic gastroparesis is prescribed metoclopramide. Which of the following statements
accurately describes the mechanism by which metoclopramide enhances gastric emptying?
A. Selective 5-HT3 receptor antagonism in the chemoreceptor trigger zone.
B. Dopamine D2 receptor antagonism in the gut and central nervous system.
C. Muscarinic M1 receptor agonism increasing lower esophageal sphincter tone.
D. Inhibition of acetylcholinesterase, prolonging acetylcholine action at neuromuscular junctions.
Correct Answer: B. Dopamine D2 receptor antagonism in the gut and central nervous system.
Rationale: Metoclopramide acts primarily as a dopamine D2 receptor antagonist in the gut, which enhances
gastric motility and accelerates gastric emptying. It also has central antiemetic effects via D2 antagonism in the
CTZ. Option A describes ondansetron, not metoclopramide. Option C is partially true but not the primary
mechanism; metoclopramide also has weak 5-HT4 agonist activity. Option D describes neostigmine, a different
drug.
Why Wrong:
A - Selective 5-HT3 antagonism is the mechanism of ondansetron, not metoclopramide.
C - Metoclopramide does not directly agonize muscarinic receptors; it enhances cholinergic activity
indirectly.
D - Acetylcholinesterase inhibition is the mechanism of neostigmine, not metoclopramide.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 63
Q3. A patient undergoing chemotherapy is prescribed a 5-HT3 receptor antagonist for prevention of acute
emesis. Which of the following properties of this drug class contributes most to its selectivity and reduced
extrapyramidal side effects compared to older antiemetics?
A. High affinity for dopamine D2 receptors in the gut.
B. Selective blockade of serotonin receptors in the area postrema and vagal afferents.
C. Ability to cross the blood-brain barrier and act on the vestibular system.
D. Antagonism of histamine H1 receptors in the vomiting center.
Page 3
, Correct Answer: B. Selective blockade of serotonin receptors in the area postrema and vagal afferents.
Rationale: 5-HT3 receptor antagonists (e.g., ondansetron) selectively block serotonin receptors located in the area postrema
(chemoreceptor trigger zone) and on vagal nerve terminals in the gut, which are key in initiating the emetic reflex. This
selectivity avoids dopamine receptor blockade, thus minimizing extrapyramidal side effects. Option A describes
metoclopramide. Option C is not a desired property; these drugs have limited CNS penetration. Option D describes
antihistamines.
Why Wrong:
A - Dopamine D2 antagonism is associated with extrapyramidal symptoms, not selectivity.
C - Vestibular system action is not a major mechanism for 5-HT3 antagonists; they act primarily on CTZ and vagus.
D - H1 antagonism is characteristic of antihistamines used for motion sickness.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 63
Q4. A patient with chronic constipation is prescribed lubiprostone. Which of the following best describes the
mechanism of action of this drug?
A. Osmotic retention of water in the intestinal lumen via non-absorbable sugars.
B. Activation of chloride channels (ClC-2) on intestinal epithelial cells, increasing fluid secretion.
C. Stimulation of peristalsis via 5-HT4 receptor agonism.
D. Inhibition of sodium-glucose cotransporters, reducing water absorption.
Correct Answer: B. Activation of chloride channels (ClC-2) on intestinal epithelial cells, increasing fluid
secretion.
Rationale: Lubiprostone is a chloride channel activator that specifically targets ClC-2 channels on the apical
membrane of intestinal epithelial cells. Activation of these channels increases chloride secretion into the lumen,
followed by sodium and water, resulting in softer stools and increased motility. Option A describes lactulose.
Option C describes prucalopride. Option D describes SGLT2 inhibitors, which are used for diabetes.
Why Wrong:
A - Osmotic laxatives like lactulose work by non-absorbable sugars, not chloride channel activation.
C - 5-HT4 agonism is the mechanism of prucalopride, not lubiprostone.
D - Inhibition of sodium-glucose cotransporters is unrelated to lubiprostone's mechanism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 65
Q5. A patient with ulcerative colitis is being treated with mesalamine. Which of the following statements
regarding the pharmacokinetics of mesalamine is most accurate?
A. Mesalamine is extensively absorbed in the small intestine and undergoes hepatic metabolism to an inactive
metabolite.
B. Mesalamine is released in the colon via pH-dependent or bacterial-dependent mechanisms, minimizing
systemic absorption.
C. Mesalamine requires activation by intestinal bacteria to form its active metabolite, 5-aminosalicylic acid.
D. Mesalamine is administered intravenously to achieve high colonic concentrations.
Correct Answer: B. Mesalamine is released in the colon via pH-dependent or bacterial-dependent
mechanisms, minimizing systemic absorption.
Rationale: Mesalamine (5-ASA) is formulated with various delivery systems (e.g., pH-dependent coatings,
bacterial-dependent release) to ensure it reaches the colon, where it acts topically. This design minimizes systemic
absorption and reduces side effects. Option A is incorrect because mesalamine is not extensively absorbed; it acts
locally. Option C is incorrect because mesalamine is already the active moiety; sulfasalazine requires bacterial
cleavage. Option D is incorrect because mesalamine is given orally or rectally, not IV.
Why Wrong:
A - Mesalamine is minimally absorbed and acts locally in the colon, not extensively absorbed.
C - Mesalamine is the active form; sulfasalazine requires bacterial reduction to release mesalamine.
D - Mesalamine is not administered intravenously; it is given orally or rectally for topical effect.
Page 4
